You will receive alerts when there are new announcements on Pharmaxis Ltd
Only registered members can use this feature.
Pharmaxis Ltd (ASX:PXS) is an Australian pharmaceutical research company with expertise in developing drugs for inflammatory and fibrotic diseases and focussed on myelofibrosis.
The company completed both its phase 1b trial of its systemic pan‐LOX inhibitor and a further phase 1 dosing study of its LOXL2 inhibitor in March.
© Proactive Investors 2019.
Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority. Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.